IL133600A0 - Compositions and methods for reducing respiratory depression and attendant side effects of mu opiod compounds - Google Patents
Compositions and methods for reducing respiratory depression and attendant side effects of mu opiod compoundsInfo
- Publication number
- IL133600A0 IL133600A0 IL13360097A IL13360097A IL133600A0 IL 133600 A0 IL133600 A0 IL 133600A0 IL 13360097 A IL13360097 A IL 13360097A IL 13360097 A IL13360097 A IL 13360097A IL 133600 A0 IL133600 A0 IL 133600A0
- Authority
- IL
- Israel
- Prior art keywords
- respiratory depression
- compounds
- animal
- reducing
- opiod
- Prior art date
Links
- 208000004756 Respiratory Insufficiency Diseases 0.000 title abstract 4
- 206010038678 Respiratory depression Diseases 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000841 delta opiate receptor agonist Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 208000002740 Muscle Rigidity Diseases 0.000 abstract 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000013160 medical therapy Methods 0.000 abstract 1
- 239000002756 mu opiate receptor agonist Substances 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000004885 piperazines Chemical class 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/887,312 US5985880A (en) | 1996-06-05 | 1997-07-03 | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
PCT/US1997/017852 WO1999001033A1 (en) | 1997-07-03 | 1997-10-01 | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
IL133600A0 true IL133600A0 (en) | 2001-04-30 |
Family
ID=25390891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13360097A IL133600A0 (en) | 1997-07-03 | 1997-10-01 | Compositions and methods for reducing respiratory depression and attendant side effects of mu opiod compounds |
Country Status (23)
Country | Link |
---|---|
US (5) | US5985880A (ru) |
EP (1) | EP1003373B1 (ru) |
JP (1) | JP2002502432A (ru) |
KR (1) | KR20010014279A (ru) |
CN (1) | CN1165308C (ru) |
AT (1) | ATE259226T1 (ru) |
AU (1) | AU756120B2 (ru) |
BR (1) | BR9714739A (ru) |
CA (1) | CA2294924C (ru) |
CZ (1) | CZ9904694A3 (ru) |
DE (1) | DE69727593D1 (ru) |
HU (1) | HUP0003842A3 (ru) |
IL (1) | IL133600A0 (ru) |
IS (1) | IS5309A (ru) |
NO (1) | NO996310L (ru) |
NZ (1) | NZ501817A (ru) |
PL (1) | PL337578A1 (ru) |
RU (1) | RU2201231C2 (ru) |
SI (1) | SI20245A (ru) |
SK (1) | SK185399A3 (ru) |
TR (1) | TR199903324T2 (ru) |
TW (1) | TW513426B (ru) |
WO (1) | WO1999001033A1 (ru) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985880A (en) * | 1996-06-05 | 1999-11-16 | Delta Pharmaceuticals | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
US6011035A (en) * | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
CN1434704A (zh) * | 1999-12-16 | 2003-08-06 | 三叉技术有限责任公司 | 延长其受体负荷剂量的治疗剂释放的系统和方法 |
SE0001207D0 (sv) * | 2000-04-04 | 2000-04-04 | Astrazeneca Canada Inc | Novel compounds |
WO2001089535A1 (en) | 2000-05-24 | 2001-11-29 | University Of Maryland Biotechnology Institute | Method for introducing and expressing genes in animal cells, and bacterial blebs for use in same |
KR100915263B1 (ko) | 2001-05-18 | 2009-09-03 | 아스트라제네카 아베 | 4(페닐-피페라지닐-메틸)벤즈아미드 유도체 및 통증, 불안증 또는 위장관 장애 치료를 위한 이들의 용도 |
NZ531875A (en) * | 2001-09-25 | 2006-10-27 | Ardent Pharmaceuticals Inc | An enantiomerically pure diarylmethylpiperazine and methods for use in the treatment for conditions such as drug addiction, mental disorders, arthritis and asthma |
US7355042B2 (en) * | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
TW200300089A (en) * | 2001-10-29 | 2003-05-16 | Ardent Pharmaceuticals Inc | Method of treating depression with delta receptor agonist compounds |
TW200301701A (en) | 2002-01-02 | 2003-07-16 | Ardent Pharmaceuticals Inc | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds |
US8476280B2 (en) * | 2002-05-09 | 2013-07-02 | Versi Group, Llc | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |
SE0203303D0 (sv) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
SE0203302D0 (sv) * | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
PT1567490E (pt) * | 2002-12-04 | 2011-12-09 | Univ Virginia Commonwealth | Agentes contra a falciformação |
US7314880B2 (en) * | 2003-01-02 | 2008-01-01 | Mount Cook Biosciences, Inc. | Cardioprotective delta opioid receptor agonists and methods of using same |
NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
US7119208B2 (en) * | 2003-12-03 | 2006-10-10 | Virginia Commonwealth University | Anti-sickling agents |
MX2007001240A (es) | 2004-08-02 | 2007-03-23 | Astrazeneca Ab | Derivados de diarilmetil-piperazina, preparaciones y usos de las mismas. |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
CN101171010B (zh) | 2005-03-07 | 2014-09-17 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
CA2643677C (en) * | 2005-04-14 | 2015-06-23 | Mount Cook Biosciences, Inc. | Compositions of novel opioid compounds and method of use thereof |
GB0606124D0 (en) * | 2006-03-28 | 2006-05-03 | Reckitt Benckiser Healthcare | Buprenorphine derivatives and uses thereof |
US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
US8883817B2 (en) * | 2007-10-18 | 2014-11-11 | Aiko Biotechnology | Combination analgesic employing opioid and neutral antagonist |
EA201491875A1 (ru) * | 2012-04-17 | 2015-04-30 | Пурдью Фарма Л.П. | Системы и способы лечения индуцированного опиоидами побочного фармакодинамического ответа |
US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
EP3393470B1 (en) | 2015-12-22 | 2021-01-20 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
ES2861774T3 (es) | 2015-12-22 | 2021-10-06 | Zogenix International Ltd | Composiciones de fenfluramina y procedimientos para prepararlas |
EP3518975A1 (en) | 2016-08-24 | 2019-08-07 | Zogenix International Limited | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
CA3061323C (en) | 2017-04-30 | 2023-09-26 | Versi Group, Llc | An opioid for use to reduce and/or treat drug addiction |
US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
CA3097335A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
EP3806835A1 (en) | 2018-06-14 | 2021-04-21 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2630435A (en) * | 1948-09-09 | 1953-03-03 | Burroughs Wellcome Co | N-benzohydryl-n-methyl piperazines and process of preparing same |
US4167574A (en) * | 1978-03-13 | 1979-09-11 | Janssen Pharmaceutica, N.V. | N-phenyl-N-(4-piperidinyl)amides |
US4518711A (en) * | 1983-05-16 | 1985-05-21 | Gibson-Stephens Institute | Conformationally constrained cyclic enkephalin analogs with delta receptor specificity |
GB8320701D0 (en) * | 1983-08-01 | 1983-09-01 | Wellcome Found | Chemotherapeutic agent |
ES2058265T3 (es) * | 1987-04-16 | 1994-11-01 | Lilly Co Eli | Piperidinas antagonistas de opiaceos. |
US4816586A (en) * | 1987-07-29 | 1989-03-28 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
IL94768A (en) * | 1989-06-19 | 1995-08-31 | Wellcome Found | Use of Reliable History Transformed by Aril for the Preparation of Pharmaceuticals |
DE415693T1 (de) * | 1989-08-28 | 1991-10-17 | Arizona Technology Development Corp., Tucson, Ariz. | Zusammensetzung und verfahren zur selektiven verstaerkung der opiat-wirkung und verminderung von opiat-toleranz und abhaengigkeit. |
EP0458160A3 (en) * | 1990-05-25 | 1992-03-18 | Sociedad Espanola De Especialidades Farmaco-Terapeuticas, S.A. | Substituted diphenylmethane derivatives as analgesic or anti-inflammatory agents |
US5159081A (en) * | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
IE914218A1 (en) * | 1991-09-11 | 1993-03-24 | Mcneilab Inc | Novel 4-arylpiperazines and 4-arylpiperidines |
US5968551A (en) | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
GB9202238D0 (en) | 1992-02-03 | 1992-03-18 | Wellcome Found | Compounds |
US5807858A (en) * | 1996-06-05 | 1998-09-15 | Delta Pharmaceutical, Inc. | Compositions and methods for reducing respiratory depression |
US5681830A (en) | 1992-02-03 | 1997-10-28 | Delta Pharmaceuticals, Inc. | Opioid compounds |
US5985880A (en) | 1996-06-05 | 1999-11-16 | Delta Pharmaceuticals | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
US5574159A (en) * | 1992-02-03 | 1996-11-12 | Delta Pharmaceuticals, Inc. | Opioid compounds and methods for making therefor |
PT711289E (pt) * | 1993-07-30 | 2001-02-28 | Delta Pharmaceuticals Inc | Compostos piperazina utilizados em terapia |
IT1270612B (it) * | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Derivati eterociclo-condensatori di morfinoidi |
US5753516A (en) * | 1995-02-03 | 1998-05-19 | Heagy; Wyrta E. | Screening method for ligands of the EBI-1 receptor |
IT1275433B (it) * | 1995-05-19 | 1997-08-07 | Smithkline Beecham Farma | Derivati di diarildiammine |
IT1277597B1 (it) * | 1995-09-15 | 1997-11-11 | Smithkline Beecham Spa | Derivati di diarilalchenilammina |
GB9709972D0 (en) | 1997-05-19 | 1997-07-09 | Pfizer Ltd | Tetrazoles |
GB9804734D0 (en) | 1998-03-05 | 1998-04-29 | Pfizer Ltd | Compounds |
-
1997
- 1997-07-03 US US08/887,312 patent/US5985880A/en not_active Expired - Fee Related
- 1997-10-01 JP JP50859899A patent/JP2002502432A/ja active Pending
- 1997-10-01 CN CNB971822719A patent/CN1165308C/zh not_active Expired - Fee Related
- 1997-10-01 DE DE69727593T patent/DE69727593D1/de not_active Expired - Lifetime
- 1997-10-01 NZ NZ501817A patent/NZ501817A/en unknown
- 1997-10-01 SK SK1853-99A patent/SK185399A3/sk unknown
- 1997-10-01 KR KR1019997012402A patent/KR20010014279A/ko not_active Application Discontinuation
- 1997-10-01 HU HU0003842A patent/HUP0003842A3/hu unknown
- 1997-10-01 SI SI9720097A patent/SI20245A/sl not_active IP Right Cessation
- 1997-10-01 BR BR9714739-7A patent/BR9714739A/pt not_active Application Discontinuation
- 1997-10-01 AT AT97910777T patent/ATE259226T1/de not_active IP Right Cessation
- 1997-10-01 AU AU48066/97A patent/AU756120B2/en not_active Ceased
- 1997-10-01 PL PL97337578A patent/PL337578A1/xx unknown
- 1997-10-01 CZ CZ19994694A patent/CZ9904694A3/cs unknown
- 1997-10-01 EP EP97910777A patent/EP1003373B1/en not_active Expired - Lifetime
- 1997-10-01 IL IL13360097A patent/IL133600A0/xx unknown
- 1997-10-01 CA CA2294924A patent/CA2294924C/en not_active Expired - Fee Related
- 1997-10-01 RU RU2000100816/14A patent/RU2201231C2/ru not_active IP Right Cessation
- 1997-10-01 TR TR1999/03324T patent/TR199903324T2/xx unknown
- 1997-10-01 WO PCT/US1997/017852 patent/WO1999001033A1/en not_active Application Discontinuation
- 1997-10-24 TW TW086115899A patent/TW513426B/zh not_active IP Right Cessation
-
1999
- 1999-07-12 US US09/352,308 patent/US6300332B1/en not_active Expired - Fee Related
- 1999-12-17 IS IS5309A patent/IS5309A/is unknown
- 1999-12-17 NO NO996310A patent/NO996310L/no not_active Application Discontinuation
-
2001
- 2001-10-09 US US09/974,004 patent/US6919350B2/en not_active Expired - Fee Related
-
2005
- 2005-07-19 US US11/184,762 patent/US20050255151A1/en not_active Abandoned
-
2008
- 2008-04-07 US US12/098,899 patent/US20080193383A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US5985880A (en) | 1999-11-16 |
WO1999001033A1 (en) | 1999-01-14 |
AU4806697A (en) | 1999-01-25 |
SI20245A (sl) | 2000-12-31 |
CZ9904694A3 (cs) | 2002-03-13 |
NO996310L (no) | 2000-02-22 |
EP1003373A1 (en) | 2000-05-31 |
SK185399A3 (en) | 2001-08-06 |
US6919350B2 (en) | 2005-07-19 |
NO996310D0 (no) | 1999-12-17 |
IS5309A (is) | 1999-12-17 |
AU756120B2 (en) | 2003-01-02 |
CA2294924C (en) | 2010-12-21 |
HUP0003842A1 (hu) | 2001-04-28 |
TW513426B (en) | 2002-12-11 |
ATE259226T1 (de) | 2004-02-15 |
KR20010014279A (ko) | 2001-02-26 |
EP1003373A4 (en) | 2000-09-20 |
PL337578A1 (en) | 2000-08-28 |
US6300332B1 (en) | 2001-10-09 |
US20020111359A1 (en) | 2002-08-15 |
TR199903324T2 (xx) | 2000-09-21 |
JP2002502432A (ja) | 2002-01-22 |
DE69727593D1 (de) | 2004-03-18 |
CN1262600A (zh) | 2000-08-09 |
NZ501817A (en) | 2002-02-01 |
EP1003373B1 (en) | 2004-02-11 |
US20080193383A1 (en) | 2008-08-14 |
HUP0003842A3 (en) | 2001-12-28 |
RU2201231C2 (ru) | 2003-03-27 |
CA2294924A1 (en) | 1999-01-14 |
US20050255151A1 (en) | 2005-11-17 |
BR9714739A (pt) | 2000-07-25 |
CN1165308C (zh) | 2004-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL133600A0 (en) | Compositions and methods for reducing respiratory depression and attendant side effects of mu opiod compounds | |
IL129410A (en) | Unit dose, sustained release oral dosage form of an opioid analgesic and a method for the preparation thereof | |
NZ319531A (en) | An analgesic synergistic composition containing a sub-analgesic dose of a mu opioid agonist and a kappa-2 opiod agonist | |
NZ508526A (en) | Opioid formulations for treating pain | |
MXPA02007690A (es) | Composiciones de liberacion controlada que contienen agonista y antiagonista de opioide. | |
BR9510168A (pt) | Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição | |
WO2000021515A3 (en) | Intranasal codeine for the rapid suppression of cough and rapid relief of pain | |
DE69214230D1 (de) | Codeinonderivate und ihre pharmazeutische Verwendung | |
WO2001087839A8 (en) | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | |
NO980700D0 (no) | Perifert aktive anti-hyperalgesi opiater | |
HU1500214D0 (hu) | Opioid agonista és antagonista hatóanyagot tartalmazó gyógyszerkészítmény | |
IL147852A0 (en) | Chemokine receptor antagonists and pharmaceutical compositions containing the same | |
AU2223095A (en) | Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules | |
NZ332215A (en) | Transdermally administered dextromethorphan as antitussive agent | |
UA66812C2 (ru) | Лекарственная форма с регулируемым высвобождением активного вещества | |
GB9721746D0 (en) | Compositions | |
CA2388395A1 (en) | Compound | |
IL126175A0 (en) | Method or treating heart failure with endothelin antagonists and pharmaceutical compositions containing the same | |
ATE212550T1 (de) | Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung | |
EP1197227A4 (en) | METHOD FOR ADMINISTERING MEDICINAL PRODUCTS WITH BINDING AFFINITY TO PLASMA PROTEIN AND USE OF THE COMPOSITION IN THE METHOD | |
GB9711032D0 (en) | Compound as a stimulant for the central nervous system | |
CA2400578A1 (en) | Controlled-release compositions containing opioid agonist and antagonist | |
WO1997004750A3 (en) | Process for preparing solid dosage forms of very low-dose drugs | |
AU5981200A (en) | Transdermal therapeutic system for administering a calcium antagonist | |
EP0097953A3 (en) | Synergistic compositions of nalbuphine and non-narcotic analgesic compounds |